Skip to main content

Month: February 2021

Tiedote johtohenkilöiden ja heidän lähipiirinsä liiketoimista: Karsten Hoppe

Written by Customer Service on . Posted in Public Companies.

Uponor Oyj     Johdon liiketoimet     16.2.2021     09.10Tiedote johtohenkilöiden ja heidän lähipiirinsä liiketoimista: Karsten HoppeMarkkinoiden väärinkäyttöasetuksen 19. artiklan mukainen ilmoitus liiketoimestaIlmoitusvelvollinenNimi: Hoppe, KarstenAsema: Muu ylin johtoLiikkeeseenlaskija: Uponor OyjLEI: 743700KA2GMSYJM3CM12Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 743700KA2GMSYJM3CM12_20210215134801_50____________________________________________Liiketoimen päivämäärä: 2021-02-15Kauppapaikka ei sovelluInstrumentti tyyppi: OSAKEISIN: FI0009002158Liiketoimen luonne: OSAKEPALKKION VASTAANOTTAMINENLiiketoimien yksityiskohtaiset tiedot(1): Volyymi: 4963 Yksikköhinta: 0.00 EURLiiketoimien yhdistetyt tiedot(1): Volyymi: 4963 Keskihinta: 0.00 EURUponor OyjSusanna InkinenViestintä- ja yritysvastuujohtajaPuh. 020 129 2081JAKELU:Nasdaq...

Continue reading

Notification of transactions by managers and their closely associated persons: William Gray

Written by Customer Service on . Posted in Public Companies.

Uponor Corporation     Managers’ Transactions     16 February 2021     09:05 EETNotification of transactions by managers and their closely associated persons: William GrayNotification under the EU Market Abuse Regulation, article 19Person subject to the notification requirementName: Gray, WilliamPosition: Other senior managerIssuer: Uponor CorporationLEI: 743700KA2GMSYJM3CM12Notification type: INITIAL NOTIFICATIONReference number: 743700KA2GMSYJM3CM12_20210215134801_51____________________________________________Transaction date: 2021-02-15Venue not applicableInstrument type: SHAREISIN: FI0009002158Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVETransaction details(1): Volume: 5574 Unit price: 0.00 EURAggregated transactions(1): Volume: 5574 Volume weighted average price: 0.00 EURUponor CorporationSusanna InkinenVice President,...

Continue reading

Tiedote johtohenkilöiden ja heidän lähipiirinsä liiketoimista: William Gray

Written by Customer Service on . Posted in Public Companies.

Uponor Oyj     Johdon liiketoimet     16.2.2021     09.05Tiedote johtohenkilöiden ja heidän lähipiirinsä liiketoimista: William GrayMarkkinoiden väärinkäyttöasetuksen 19. artiklan mukainen ilmoitus liiketoimestaIlmoitusvelvollinenNimi: Gray, WilliamAsema: Muu ylin johtoLiikkeeseenlaskija: Uponor OyjLEI: 743700KA2GMSYJM3CM12Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 743700KA2GMSYJM3CM12_20210215134801_51____________________________________________Liiketoimen päivämäärä: 2021-02-15Kauppapaikka ei sovelluInstrumentti tyyppi: OSAKEISIN: FI0009002158Liiketoimen luonne: OSAKEPALKKION VASTAANOTTAMINENLiiketoimien yksityiskohtaiset tiedot(1): Volyymi: 5574 Yksikköhinta: 0.00 EURLiiketoimien yhdistetyt tiedot(1): Volyymi: 5574 Keskihinta: 0.00 EUR Uponor OyjSusanna InkinenViestintä- ja yritysvastuujohtajaPuh. 020 129 2081JAKELU:Nasdaq...

Continue reading

Adevinta ASA (ADE) – Proposed Acquisition of eBay Classifieds Group: Update from the UK Competition & Markets Authority

Written by Customer Service on . Posted in Public Companies.

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THESECURITIES DESCRIBED HEREIN.Oslo, 16 February 2021 – Today, Adevinta ASA (ADE) (“Adevinta” or the Company”) confirms that the UK Competition and Markets Authority (CMA) has announced that it has concerns that Adevinta’s proposed acquisition of eBay Classifieds Group from eBay Inc (“eBay”) could reduce competition in the UK, following its Phase 1 review. -Ends-Notes to EditorContactsMélodie LarocheHead of Corporate Communications+33 (0) 6 84 30 52 76melodie.laroche@adevinta.com /press@adevinta.comMarie de ScorbiacHead...

Continue reading

Willis Towers Watson enhances its human capital data science capabilities globally with the addition of the Jobable team

Written by Customer Service on . Posted in Public Companies.

LONDON, Feb. 16, 2021 (GLOBE NEWSWIRE) — Willis Towers Watson (NASDAQ: WLTW), a leading global advisory, broking and solutions company, today announced a group hire of the entire team from Jobable, a Hong Kong-based human capital analytics and software company. The team brings to Willis Towers Watson (WTW) its expertise in human capital data science and software development. Combining the capabilities of Jobable and WTW will enhance the company’s leadership in helping organisations drive digital transformation and uncover the insights within their human capital data.Former Jobable Chief Executive Officer, Richard Hanson, joins WTW as Global Head of Data Science for Talent & Rewards, along with his Jobable co-founder, Luke Byrne. In his new role, Hanson will continue to be based in Hong Kong, working to identify and capture...

Continue reading

EfTEN Real Estate Fund III AS unaudited consolidated interim accounts for the 4th quarter and 12 months of 2020

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Comment of the fund managerThe main economic event of 2020 was not an economic event – unexpected arrival and spread of coronavirus. The virus wave that reached the Baltics in February 2020, closed the economy and put a significant strain on the fund’s cash flows but only in short term. The fund’s management found temporary solutions with the tenants, which usually resulted in a temporary rent discount for 3-4 months and an equivalent extension of the lease period.The second wave of virus, which started in the fall was significantly worse in medical terms compared to the outbreak in spring, however, the companies had a much calmer attitude towards the second wave compared to the first wave. Coronavirus will definitely have an effect to fund’s cash flows in the first quarter of 2021, but the positive news related to vaccine give hope that...

Continue reading

EfTEN Real Estate Fund III AS 2020. aasta IV kvartali ja 12 kuu auditeerimata majandustulemused

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Fondijuhi kommentaar2020. aasta põhiliseks majandussündmuseks oli seekord mitte-majandussündmus – koroonaviiruse ootamatu tulek ja levik. 2020. aasta veebruaris. Balti riikidesse jõudnud viiruselaine sulges majanduse ja survestas olulisel määral fondi rahavooge kuid seda siiski lühiajaliselt. Fondi juhtkond leidis üürnikega lahendused ajutiste üürialandamise kokkulepete näol, mis reeglina päädisid 3-4 kuulise ajutise üürisoodustusega ning üürilepingu perioodi samaväärse pikendamisega. Sügisel alanud viiruslaine teine faas oli meditsiiniliste indikaatorite alusel oluliselt halvem kui kevade puhang, kuid ettevõtted suhtusid teise lainesse palju rahulikumalt kui see oli esimese laine puhul. Kindlasti avaldab koroona oma mõju fondi rahavoogudele ka 2021. aasta esimeses kvartalis, kuid positiivsed uudised vaktsiinirindelt annavad lootust,...

Continue reading

Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets

Written by Customer Service on . Posted in Public Companies.

Double-digit growth in Cresemba and Zevtera non-deferred revenue contributionsOperating loss reduced by over 50% to CHF 8.2 millionImproved operating cash flow by 15%, CHF 167 million year-end cash and financial investmentsEstablished clinical proof of concept for derazantinib as monotherapy in first cancer indication2021 guidance: expecting 38% – 51% growth in Cresemba and Zevtera non-deferred revenue contributions, stable expenses and 2021 year-end cash position of CHF 110 – 120 millionBasel, Switzerland, February 16, 2021Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the financial year ended December 31, 2020.David Veitch, Chief Executive Officer, said: “Despite the coronavirus pandemic, we have remained fully operational and have achieved significant milestones throughout 2020, both in...

Continue reading

Basilea meldet für 2020 starke Finanzergebnisse und deutliche Fortschritte in ihrer klinischen Onkologie-Pipeline

Written by Customer Service on . Posted in Public Companies.

Zweistelliges Wachstum der direkt realisierten Umsatzbeiträge durch Cresemba und ZevteraBetriebsverlust um mehr als 50 % auf CHF 8.2 Mio. verringertUm 15% verbesserter Cashflow aus operativer Geschäftstätigkeit, zum Jahresende CHF 167 Mio. liquide Mittel und FinanzanlagenKlinischer Wirksamkeitsnachweis (Proof of Concept) für Derazantinib-Monotherapie in erster Krebs-Indikation erbrachtAusblick 2021: 38 % – 51 % Wachstum der direkt realisierten Umsatzbeiträge von Cresemba und Zevtera erwartet, ausserdem stabile Ausgaben und Cash-Position zum Jahresende von CHF 110 – 120 Mio.Basel, 16. Februar 2021Basilea Pharmaceutica AG (SIX: BSLN) gab heute ihre Finanzergebnisse für das am 31. Dezember 2020 beendete Geschäftsjahr bekannt.David Veitch, Chief Executive Officer, sagte: „Trotz der Coronavirus-Pandemie sind wir voll einsatzfähig...

Continue reading

Czech Republic First European Country to Grant National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product

Written by Customer Service on . Posted in Public Companies.

MELBOURNE, Australia and LIÈGE, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the Ministry of Health of the Czech Republic is the first European health authority to grant a national authorisation allowing the use of TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11), a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA) for the imaging of prostate cancer using Positron Emission Tomography (PET).The national authorisation, which is specific to Telix’s prostate cancer imaging product, enables Czech physicians to use TLX591-CDx under a Specific Therapeutic Programme (STP), which allows medical products intended for the treatment, prevention or diagnosis of conditions severely affecting human health to be used prior to being granted...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.